Articles tagged "Antibodies"

2021 American Transplant Congress
The Clinical Significance of Preformed C1q-binding Donor-specific HLA Antibodies in Kidney Transplantation
S. Lee¹, C. Yang², B. Chung²
¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: Complement activation is one dominant mechanism which cause allograft injury in kidney transplantation (KT). Anti-HLA donor-specific antibodies (DSA) that bind to HLA molecules on…
2020 American Transplant Congress
Identification of the dnDSA Inducing HLA Mismatches Across Multiple Renal Transplant Centers: A 3-Year Longitudinal Analysis of >11,000 HLA Mismatches in 2271 Patients
J. M. Brennan¹, M. D. Stegall², C. A. Schinstock², R. L. Heilman³, L. M. Rebellato⁴, M. D. Samaniego-Picota⁵, D. Lesser⁴, M. J. Ghandi², J. L. Beaumont¹, M. J. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴East Carolina University, Greenville, NC, ⁵Henry Ford Transplant Institute, Detroit, MI
*Purpose: The presence of a mismatch (MM) between donor and recipient HLA does not always lead to the patient developing a de novo donor-specific anti-HLA…
2020 American Transplant Congress
Unusual Case of Delayed Onset Proteinuria in AT1R Antibody Mediated Rejection
K. Venkatachalam, L. Mackelaite, H. Dave
Nephrology and Hypertension, University of Louisville, Louisville, KY
*Purpose: Describing the nuances in treatment of Angiotensin receptor II Type I antibody mediated rejection*Methods: Complement-independent Angiotensin receptor II Type I antibodies (AT1R-Ab) have been…
2020 American Transplant Congress
Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377)
S. C. Jordan, N. Ammerman, M. Toyoda, S. Ge, E. Huang, A. Peng, S. Sethi, R. Najjar, E. Ortiz, M. Chu, A. De Guzman, I. Kim, K. Lim, J. Choi, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2020 American Transplant Congress
Impact of Kidney Transplant Type and Previous Transplant on Baseline Donor-Derived Cell Free DNA
K. K. Sureshkumar, B. Chopra
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA
*Purpose: Donor derived-cell free DNA (dd-cfDNA) is a biomarker useful in predicting acute rejection in renal allografts. The technology uses next generation sequencing and does…
2020 American Transplant Congress
Activation of the ICOS/ICOS-Ligand Pathway in Antibody-Mediated Kidney Graft Rejection
V. Cantaluppi¹, G. Merlotti¹, M. Quaglia¹, G. Rosso¹, N. Clemente¹, G. Cappellano¹, A. Chiocchetti¹, G. Castellano², U. Dianzani¹, G. Camussi³
¹Nephrology and Kidney Transplantation Unit, University of Piemonte Orientale (UPO), Novara, Italy, ²Nephrology, Dialysis and Kidney Transplantation Unit, University of Foggia, Foggia, Italy, ³Department of Medical Sciences, University of Torino, Torino, Italy
*Purpose: The costimulatory pathway ICOS/ICOS-Ligand may represent a new therapeutic target in antibody-mediated rejection (ABMR), the major cause of long term kidney graft failure. The…
2020 American Transplant Congress
Effect of Therapeutic Plasma Exchange on Glomerular Filtration Rate in Patients with Acute Humoral Rejection
M. Maza Moreno, S. Hernandez-Estrada, J. Cano Cervantes, D. Maldonado Tapia, M. Alamilla Sanchez
Nephrology and Transplant Division, CMN 20 de Noviembre, Ciudad de Mexico, Mexico
*Purpose: AMR is the main risk factor for graft loss, especially after the first post transplant year. Up to 80% of patients achieve response with…
2020 American Transplant Congress
Post-Transplant Collagen I and Collagen III Antibodies and Antibody-Mediated Rejection in Kidney Transplantation Recipients
S. Park¹, S. Yang², J. Kim², Y. Kim², Y. Kim², J. Ha², K. Moon², E. Song², H. Lee²
¹Armed Forces Capital Hospital, Gyeonggi-do, Korea, Republic of, ²Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: An emerging role of non-human leukocyte antigen (HLA) antibodies on the risk of antibody-mediated rejection (AMR) has been suggested, although most of their non-HLA…
2020 American Transplant Congress
Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
Y. Kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Regulation, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Owing to limited organ availability, ABO-incompatible living kidney transplantation (ABO-ILKT) has been used extensively. Various forms of preconditioning therapies have been used alone or…
2020 American Transplant Congress
Missing Self Increases the Incidence of Microvascular Inflammation after Kidney Transplantation
J. Callemeyn¹, A. Senev², M. Coemans¹, E. Lerut³, B. Sprangers¹, D. Kuypers¹, A. Koenig⁴, O. Thaunat⁴, M. Emonds², M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²Histocompatibility and Immunogenetics Laboratory, Red Cross-Flanders, Mechelen, Belgium, ³Imaging and Pathology, KU Leuven, Leuven, Belgium, ⁴INSERM U1111, Université Claude Bernard Lyon I, Lyon, France
*Purpose: Anti-HLA donor-specific antibodies (HLA-DSA) are often absent in serum of kidney allograft recipients with biopsies demonstrating microvascular inflammation (MVI), the histological hallmark of antibody-mediated…